DE
Pioneering a new class of anti-cancer small molecules
About Us
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel treatments to help people suffering from a range of oncologic and onco-dermatologic diseases.
Our Science
Vidac Novel Chemical Entities (VDA-NCEs) reverse the Warburg effect by disabling the anchoring of HK2 to the VDAC pores. The metabolism reverses towards its normal state, inhibiting tumor hyper growth, reactivating the immune response, and stopping cancer proliferation.
Pipeline
Vidac is developing a strong pipeline of first-in-class anti-cancer drugs. VDA-1102, our first drug candidate, targets advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL).
Pioneering a new class of anti-cancer small molecules
About Us
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel treatments to help people suffering from a range of oncologic and onco-dermatologic diseases.
Our Science
Vidac Novel Chemical Entities (VDA-NCEs) reverse the Warburg effect by disabling the anchoring of HK2 to the VDAC pores. The metabolism reverses towards its normal state, inhibiting tumor hyper growth, reactivating the immune response, and stopping cancer proliferation.
Pipeline
Vidac is developing a strong pipeline of first-in-class anti-cancer drugs. VDA-1102, our first drug candidate, targets advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL).

Vidac Molecules Have the Potential to Inhibit Cell Growth Across a Wide Range of Cancers

In a comprehensive study involving 57 different cancer models, 70% of the cases showed promising therapeutic efficacy.

vidac pharma: vda1102 inhibits cancer

Therapeutic Areas

Vidac is creating innovative therapies for people suffering from a range of oncologic and dermatologic medical conditions.

Learn More